Multiple myeloma is a type of blood cancer that affects plasma cells, a crucial component of the immune system. Globally, it ranks 24th among the most common cancers, accounting for approximately 1% of all cancer cases. Despite advancements, there remains a high unmet clinical need for more effective therapies, as current treatments such as proteasome inhibitors and immunomodulatory drugs often fail to provide long-term remission. The growing focus on targeted therapies, immune checkpoint inhibitors, and CAR-T cell therapies is expected to drive the development of promising multiple myeloma drug candidates. These innovations hold the potential to enhance treatment outcomes in the coming years.
Major companies involved in the multiple myeloma pipeline drugs market include Pfizer, Amgen, and others.
Leading drugs currently in the pipeline include Elranatamab, BCD-264, GR1803 injection, and others.
The increased focus on novel therapies, including targeted treatments, immune checkpoint inhibitors, and CAR-T cell therapies, are expected to positively influence the multiple myeloma pipeline landscape.
The Multiple Myeloma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into multiple myeloma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for multiple myeloma. The multiple myeloma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The multiple myeloma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with multiple myeloma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to multiple myeloma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Multiple myeloma is a blood cancer that affects plasma cells, causing abnormal protein production, bone damage, and immune dysfunction. It arises from genetic mutations and bone marrow changes that drive uncontrolled cell growth. The multiple myeloma drug pipeline is expanding with immunotherapies, CAR-T cell therapies, bispecific antibodies, and next-generation proteasome inhibitors, aiming to improve treatment efficacy and patient survival.
Multiple myeloma treatment includes proteasome inhibitors, immunomodulators, monoclonal antibodies, and chemotherapy. Advancements include CAR-T cell therapies, bispecific T-cell engagers, and novel inhibitors. Stem cell transplantation remains vital for eligible patients. Emerging therapies focus on overcoming drug resistance and improving remission rates.
Multiple myeloma accounts for 1% to 1.8% of all cancer cases globally and is the second most common hematological malignancy. In 2025, the United States is expected to report 36,110 new cases. The United Kingdom records approximately 6,000 diagnoses and 3,000 deaths annually. In India, multiple myeloma incidence is rising, with higher rates in men at 1.13 per 100,000 compared to women at 0.81 per 100,000.
This section of the report covers the analysis of multiple myeloma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total multiple myeloma clinical trials.
The drug molecule categories covered under the multiple myeloma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, and biologics. The multiple myeloma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for multiple myeloma.
The EMR report for the multiple myeloma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed multiple myeloma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in multiple myeloma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for multiple myeloma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of multiple myeloma drug candidates.
The Elranatamab post-trial access study, sponsored by Pfizer, aims to evaluate the continued clinical benefit of Elranatamab monotherapy in multiple myeloma participants. This Phase 4 study is designed as an open-label, single-arm trial. It is expected to be completed by February 22, 2032, with approximately 80 participants enrolled.
Biocad is sponsoring a Phase 3 study, DARVIVA, to examine the efficacy and safety of BCD-264 and Darzalex as monotherapy in patients with relapsed and refractory multiple myeloma. The objective is to compare the two drugs' profiles in subjects previously treated with proteasome inhibitors and immunomodulatory drugs. The study is expected to be completed by July 2026, enrolling around 252 participants.
Genrix (Shanghai) Biopharmaceutical Co., Ltd. is sponsoring a Phase II study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of GR1803 injection in patients with relapsed/refractory multiple myeloma. The study aims to assess treatment response and tolerability. The study is expected to be completed by August 1, 2027, with an estimated enrollment of 116 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Multiple Myeloma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for multiple myeloma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into multiple myeloma collaborations, regulatory environments, and potential growth opportunities.
Global Cancer Screening Market
Global Cancer Therapeutics Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share